FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140052555> ?p ?o ?g. }

• W2140052555 endingPage "3621" @default.
• W2140052555 startingPage "3612" @default.
• W2140052555 abstract "BACKGROUND Ibrutinib is active in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). In patients treated with ibrutinib for R/R CLL, del(17p), identified by interphase fluorescence in situ hybridization (FISH), is associated with inferior progression-free survival despite equivalent initial response rates. Del(17p) is frequently associated with a complex metaphase karyotype (CKT); the prognostic significance of CKT in ibrutinib-treated patients has not been reported. METHODS This study reviewed 88 patients treated for R/R CLL at The University of Texas MD Anderson Cancer Center with investigational ibrutinib-based regimens from 2010 to 2013. Pretreatment FISH and lipopolysaccharide-stimulated metaphase cytogenetic analysis were performed on bone marrow. RESULTS An adequate pretreatment metaphase karyotype was available for 56 of the 88 patients. The karyotype was complex in 21 of the 56 cases; 17 of the 21 had del(17p) according to FISH. The overall response rate, including partial remission with persistent lymphocytosis, was 94%; 18% had complete responses. In a multivariate analysis (MVA), only CKT was significantly associated with event-free survival (EFS; hazard ratio [HR], 6.6 [95% CI 1.7-25.6]; P = .006). Fludarabine-refractory CLL (HR, 6.9 [95% CI 1.8-27.1], P = .005) and CKT (HR 5.9 [95% CI 1.6-22.2], P = .008) were independently associated with inferior overall survival (OS) in MVA. Del(17p) by FISH was not significantly associated with EFS or OS in MVA. CONCLUSIONS CKT is a powerful predictor of outcomes for ibrutinib-treated patients with R/R CLL and may be a stronger predictor of biological behavior than del(17p) by FISH. Because of their relatively poor outcomes, patients with CKT are ideal candidates for studies of consolidative treatment strategies or novel treatment combinations. Cancer 2015 © 2015 American Cancer Society. Cancer 2015;121:3612–3621. © 2015 American Cancer Society." @default.
• W2140052555 created "2016-06-24" @default.
• W2140052555 creator A5006104041 @default.
• W2140052555 creator A5008352184 @default.
• W2140052555 creator A5021380291 @default.
• W2140052555 creator A5027575595 @default.
• W2140052555 creator A5028845635 @default.
• W2140052555 creator A5058755419 @default.
• W2140052555 creator A5074353547 @default.
• W2140052555 creator A5080883357 @default.
• W2140052555 creator A5084290698 @default.
• W2140052555 creator A5089428686 @default.
• W2140052555 creator A5090435894 @default.
• W2140052555 date "2015-07-20" @default.
• W2140052555 modified "2023-10-17" @default.
• W2140052555 title "Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens" @default.
• W2140052555 cites W1564039428 @default.
• W2140052555 cites W1974878450 @default.
• W2140052555 cites W2000774530 @default.
• W2140052555 cites W2006486191 @default.
• W2140052555 cites W2015687515 @default.
• W2140052555 cites W2024216962 @default.
• W2140052555 cites W2038252730 @default.
• W2140052555 cites W2041925366 @default.
• W2140052555 cites W2052177425 @default.
• W2140052555 cites W2064167298 @default.
• W2140052555 cites W2067064694 @default.
• W2140052555 cites W2071549499 @default.
• W2140052555 cites W2074584895 @default.
• W2140052555 cites W2091416193 @default.
• W2140052555 cites W2140606816 @default.
• W2140052555 cites W2150487985 @default.
• W2140052555 cites W2153188399 @default.
• W2140052555 cites W2167835161 @default.
• W2140052555 cites W2473561901 @default.
• W2140052555 cites W304227101 @default.
• W2140052555 cites W4293241248 @default.
• W2140052555 doi "https://doi.org/10.1002/cncr.29566" @default.
• W2140052555 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4866653" @default.
• W2140052555 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26193999" @default.
• W2140052555 hasPublicationYear "2015" @default.
• W2140052555 type Work @default.
• W2140052555 sameAs 2140052555 @default.
• W2140052555 citedByCount "216" @default.
• W2140052555 countsByYear W21400525552015 @default.
• W2140052555 countsByYear W21400525552016 @default.
• W2140052555 countsByYear W21400525552017 @default.
• W2140052555 countsByYear W21400525552018 @default.
• W2140052555 countsByYear W21400525552019 @default.
• W2140052555 countsByYear W21400525552020 @default.
• W2140052555 countsByYear W21400525552021 @default.
• W2140052555 countsByYear W21400525552022 @default.
• W2140052555 countsByYear W21400525552023 @default.
• W2140052555 crossrefType "journal-article" @default.
• W2140052555 hasAuthorship W2140052555A5006104041 @default.
• W2140052555 hasAuthorship W2140052555A5008352184 @default.
• W2140052555 hasAuthorship W2140052555A5021380291 @default.
• W2140052555 hasAuthorship W2140052555A5027575595 @default.
• W2140052555 hasAuthorship W2140052555A5028845635 @default.
• W2140052555 hasAuthorship W2140052555A5058755419 @default.
• W2140052555 hasAuthorship W2140052555A5074353547 @default.
• W2140052555 hasAuthorship W2140052555A5080883357 @default.
• W2140052555 hasAuthorship W2140052555A5084290698 @default.
• W2140052555 hasAuthorship W2140052555A5089428686 @default.
• W2140052555 hasAuthorship W2140052555A5090435894 @default.
• W2140052555 hasBestOaLocation W21400525551 @default.
• W2140052555 hasConcept C126322002 @default.
• W2140052555 hasConcept C143998085 @default.
• W2140052555 hasConcept C207103383 @default.
• W2140052555 hasConcept C2776694085 @default.
• W2140052555 hasConcept C2776755627 @default.
• W2140052555 hasConcept C2777938653 @default.
• W2140052555 hasConcept C2778461978 @default.
• W2140052555 hasConcept C2779263901 @default.
• W2140052555 hasConcept C2779878957 @default.
• W2140052555 hasConcept C44249647 @default.
• W2140052555 hasConcept C71924100 @default.
• W2140052555 hasConcept C90924648 @default.
• W2140052555 hasConceptScore W2140052555C126322002 @default.
• W2140052555 hasConceptScore W2140052555C143998085 @default.
• W2140052555 hasConceptScore W2140052555C207103383 @default.
• W2140052555 hasConceptScore W2140052555C2776694085 @default.
• W2140052555 hasConceptScore W2140052555C2776755627 @default.
• W2140052555 hasConceptScore W2140052555C2777938653 @default.
• W2140052555 hasConceptScore W2140052555C2778461978 @default.
• W2140052555 hasConceptScore W2140052555C2779263901 @default.
• W2140052555 hasConceptScore W2140052555C2779878957 @default.
• W2140052555 hasConceptScore W2140052555C44249647 @default.
• W2140052555 hasConceptScore W2140052555C71924100 @default.
• W2140052555 hasConceptScore W2140052555C90924648 @default.
• W2140052555 hasIssue "20" @default.
• W2140052555 hasLocation W21400525551 @default.
• W2140052555 hasLocation W21400525552 @default.
• W2140052555 hasLocation W21400525553 @default.
• W2140052555 hasOpenAccess W2140052555 @default.
• W2140052555 hasPrimaryLocation W21400525551 @default.
• W2140052555 hasRelatedWork W2106082064 @default.
• W2140052555 hasRelatedWork W2754654824 @default.

• next